High-dose-rate brachytherapy for eyelid carcinoma: Implant technique and review

Journal of Contemporary Brachytherapy · Published 2025-01-01 · DOI 10.5114/jcb.2025.158163

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.5114/jcb.2025.158163

Abstract

Eyelid carcinoma is a tumor often detected at an early stage, which can be managed surgically. In non-surgical cases, brachytherapy is a valid alternative or as adjuvant therapy when risk factors exist. Basal cell carcinoma is the most common type of eyelid cancer, usually occurring in the lower eyelid. Interstitial technique with plastic tubes is a simple procedure in this location. High-dose rate (HDR) brachytherapy offers local control rates greater than 94%, with few side effects and good function preservation. This article provided practical description of the technique and review of literature. Collaboration between ophthalmology, dermatology, and brachytherapy specialists is essential to achieve the best patient outcomes.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year
2025

Related articles